Evidence map›Paper›PMID 41251034›Full record

ArticleJournal of pediatric gastroenterology and nutrition2026

Vedolizumab for extraintestinal manifestations in pediatric inflammatory bowel disease: Results from the VedoKids study.

Giulia D'Arcangelo, Dan Turner, Oren Ledder, Esther Orlanski-Meyer, Efrat Broide, Maya Granot, Manar Matar, Seamus Hussey, Anat Yerushalmy-Feler, Christoph Norden and 2 more

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02862132 (Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02862132 nacompletednot on this map

Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)

TypeinterventionalSponsorShaare Zedek Medical CenterRan2017 to 2022Enrolled142ConditionsCrohn's Disease, Ulcerative Colitis, Inflammatory Bowel DiseaseArmsVedolizumab
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Giulia D'ArcangeloGastroenterology, Hepatology and Cystic Fibrosis Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Dan TurnerThe Juliet Keidan Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, Jerusalem, Israel.
Oren LedderThe Juliet Keidan Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, Jerusalem, Israel.
Esther Orlanski-MeyerThe Juliet Keidan Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, Jerusalem, Israel.
Efrat BroideDivision of Digestive Diseases, Shamir Medical Center, Be'er Ya'akov, Israel.
Maya GranotDivision of Pediatric Gastroenterology and Nutrition, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.
Manar MatarGray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Seamus HusseyNational Centre for Paediatric Gastroenterology, Children's Health, Dublin, Ireland.
Anat Yerushalmy-FelerGray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Christoph NordenDepartment for Children and Young People, Hvidovre University Hospital, Copenhagen, Denmark.
Erasmo MieleDepartment of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II", Naples, Italy.
Marina AloiGastroenterology, Hepatology and Cystic Fibrosis Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy.ORCID https://orcid.org/0000-0001-7404-4004

Funding

European Society for Paediatric Gastroenterology Hepatology and NutritionTakedaThe European Crohn's and Colitis Organization
6 · The paper itself

Abstract

Extraintestinal manifestations (EIMs) manifest in 6%-47% of patients with inflammatory bowel disease (IBD). Here, we characterize the course of EIMs in pediatric patients receiving vedolizumab included in the VedoKids cohort study. This was a subgroup analysis of the pediatric VedoKids cohort, a multicenter, prospective study of children (aged 0-18 years) with IBD treated with vedolizumab and followed through 54 weeks. EIMs were identified in 18/142 (12.6%) children at baseline; 56% of these cases were articular EIMs; the EIMs resolved in 89% within 18 months. Concomitant medications were administered in 72% of EIM cases, most of which were ongoing at the time of vedolizumab initiation. Of the 124 children without EIMs, five (4%) developed EIMs during follow up: three arthritis, two cutaneous manifestations. The presence of EIMs did not affect the durability of vedolizumab treatment. In conclusion, most EIMs in children with IBD resolved with vedolizumab treatment, but almost half received concomitant medications. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02862132. https://clinicaltrials.gov/study/NCT02862132?term=NCT02862132&rank=1.

Indexed as

Antibodies, Monoclonal, HumanizedGastrointestinal AgentsInflammatory Bowel DiseasesAdolescentChildChild, PreschoolFemaleHumansInfantInfant, NewbornMaleProspective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedGastrointestinal Agentsvedolizumabbiologic therapychildrenprospective datareal‐world evidencetreatment outcomes

Identifiers

PMID41251034
PMCPMC12864168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.